315 related articles for article (PubMed ID: 25241939)
1. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Taieb G; Renard D; Thouvenot E; Servillo G; Castelnovo G
J Neurol Sci; 2014 Nov; 346(1-2):364-5. PubMed ID: 25241939
[No Abstract] [Full Text] [Related]
2. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
3. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
4. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
[TBL] [Abstract][Full Text] [Related]
5. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Hoepner R; Ahlbrecht J; Faissner S; Schneider R; Dahlhaus S; Adams O; Raab P; Lukas C; Chan A; Stangel M; Gold R
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1177-8. PubMed ID: 24700881
[No Abstract] [Full Text] [Related]
6. Deaths and disability from natalizumab are no longer tolerable: Commentary.
Hutchinson M
Mult Scler; 2012 Aug; 18(8):1073. PubMed ID: 22807472
[No Abstract] [Full Text] [Related]
7. Deaths and disability from natalizumab are no longer tolerable: Yes.
Duquette P
Mult Scler; 2012 Aug; 18(8):1068-9. PubMed ID: 22807470
[No Abstract] [Full Text] [Related]
8. Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem.
Havla J; Hohlfeld R; Kümpfel T
J Neurol; 2014 Jan; 261(1):232-4. PubMed ID: 24276521
[No Abstract] [Full Text] [Related]
9. Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
Sørensen PS
Mult Scler; 2012 Aug; 18(8):1070-2. PubMed ID: 22807471
[No Abstract] [Full Text] [Related]
10. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
11. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
12. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
Travasarou M; Marousi S; Papageorgiou E; Karageorgiou CE
Clin Neurol Neurosurg; 2013 Jun; 115(6):827-9. PubMed ID: 22920632
[No Abstract] [Full Text] [Related]
13. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Maillart E; Louapre C; Lubetzki C; Papeix C
Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
16. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L
Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
[TBL] [Abstract][Full Text] [Related]
17. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
Ercan MB; Kocer B; Altiparmak T; Arslan I
Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206
[No Abstract] [Full Text] [Related]
18. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
Alvarez-Cermeño JC; Masjuan J; Villar LM
N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16240475
[No Abstract] [Full Text] [Related]
19. Rituximab in relapsing-remitting multiple sclerosis.
Schrijver HM
N Engl J Med; 2008 Jun; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
[No Abstract] [Full Text] [Related]
20. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
Wattjes MP; Verhoeff L; Zentjens W; Killestein J; van Munster ET; Barkhof F; van Eijk JJ
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1176-7. PubMed ID: 23695498
[No Abstract] [Full Text] [Related]
[Next] [New Search]
